EUCTR2008-006009-18-DE进行中（未招募）不适用
An open-label, Proof-of-Concept trial in treatment-naïve HIV-1- infected subjects to evaluate the antiviral activity of a single intramuscular dosing of TMC278LA as monotherapy.
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria.
- •1. Male or female subjects, aged 18 to 60 years, extremes included.
- •2. Documented HIV-1 infection for at least 6 months prior to screening.
- •3. ICF signed voluntarily before the first trial-related activity.
- •4. Able to comply with the protocol requirements and having good accessible veins.
- •5. HIV-1 plasma viral load at screening visit above 5000 HIV-1 RNA copies/mL.
- •6. CD4 cell count of at least 200 cells/mm3.
- •7. Subject has not been treated with a therapeutic HIV vaccine within 1 year prior to screening and has never been treated with an ARV drug (including investigational) prior to screening.
- •8. Subject agrees not to start ARV therapy (ART) before the baseline visit.
- •9. Subject agrees to start an investigator-selected oral standard-of-care HAART regimen on Day 8 of the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects must not have any of the following characteristics.
- •1. Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the subject’s safety and adherence to the protocol.
- •2. Subjects with any active or chronic hepatic disease.
- •3. Subject has documented acute HIV-1 infection.
- •4. Pre-existing ARV drug resistance for NRTIs and NNRTIs (to be determined by the Protocol Virologist) based on genotype testing on HIV-1 virus. The following list of NNRTI RAMs was compiled based on the list of IAS-USA NNRTI RAMs10 and other relevant publications:
- •A098G K103T E138R Y188L F227C
- •L100I V106A V179D G190A M230I
- •K101E V106M V179E G190C M230L
- •K101P V108I Y181C G190E P236L
- •K101Q E138A Y181I G190Q K238N
- •K103H E138G Y181V G190S K238T
- •K103N E138K Y188C G190T Y318F
- •K103S E138Q Y188H P225H
- •5. Life expectancy of less than 6 months.
- •6. Subject has any currently active Acquired Immunodeficiency Syndrome (AIDS) defining illness (Category C conditions according to the Centers for Disease Control [CDC] Classification System for HIV Infection 1993, refer to Addendum 5: HIV-Related Events or Outcomes) with the following exceptions (to be discussed with the Sponsor prior to enrollment):
- •- Stable, cutaneous Kaposi’s Sarcoma (i.e., no pulmonary or gastrointestinal involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the trial period;
- •- Wasting syndrome due to HIV infection if, in the investigator’s opinion, is not actively progressive and its treatment does not require hospitalization or compromise the subject’s safety or compliance to adhere to the trial protocol procedures. If the subject is on maintenance therapy (which may include human growth hormone, appetite stimulants and anabolic steroids) for previously diagnosed wasting, he/she may be eligible for the trial only if such treatment is not included in the list of disallowed medications.
- •Note: Primary or secondary prophylaxis for an AIDS defining illness is allowed in case the medication used is not part of the disallowed medication.
- •7. Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction), or findings during screening or medical history or physical examination that, in the investigator’s opinion, would compromise the outcome of the trial.
- •8. Receipt of any investigational medication or any prophylactic vaccine within 90 days prior to the trial investigational medication administration.
- •9. Previously demonstrated clinically significant allergy or hypersensitivity (e.g., have a strong family history of rash, or multiple allergies).
- •10. Vulnerable subjects (e.g., persons kept in detention).
- •11. Pregnant or breastfeeding female.
- •12. Non-vasectomized heterosexually active males without the use of effective birth control methods or not willing to continue practicing these birth control methods from screening onwards until the first 30 days after dosing. As of Day 8, the label of HAART should be followed (see Section 5.2.4).
- •13. Female of childbearing potential without the use of effective birth control methods or not willing to continue practicing these birth control methods from screening onwards until the first 30 days after dosing. As from Day 8, the label of HAART should be followed (see Section 5.2.4).
- •Note: Hormone-based contraception may not be reliable when taking TMC278LA;
- •therefore, to be eligible for this trial, women of childbearing potential should either:
研究者
相似试验
已完成
不适用
Open randomized study for the evaluation of activities of AS/AQ (co-packaged and co-formulated) versus AL on asexual & sexual paraistes in childrePaediatricsMalariaPACTR201508001188143Swiss Pharma Nigeria Limited
已完成
不适用
Pharmacodynamics/electroencephalographic (EEG) study with Ginkgo biloba special extract EGb 761®Mild cognitive deficitsMental and Behavioural DisordersISRCTN50622732Dr. W. Schwabe GmbH & Co. KG (Germany)20
进行中（未招募）
1 期
Prospective, open-label, monocenter, trial to investigate the efficacy and tolerability of Vagisan® a lactic acid containing vaginal suppository, in a panel of post-menopausal women suffering from vulvo vaginal atrophy (VVA)vulvovaginal atrophyMedDRA version: 21.1Level: LLTClassification code 10047782Term: Vulvovaginal atrophySystem Organ Class: 100000004872EUCTR2019-002325-30-DEDr. August Wolff GmbH & Co. KG Arzneimittel43
招募中
4 期
Intravitreal Aflibercept for the Treatment of Treatment Resistant Macular Oedema secondary to Retinal Vein Occlusionsmacular oedema secondary to retinal vein occlusionACTRN12617001487303A/Prof Andrew Chang50
尚未招募
1 期
Clinical evaluation of custom-made bracketsmalocclusionJPRN-jRCTs022230061Kanetaka Hiroyasu26